Condition
Irritable Bowel Syndrome - Diarrhoea
Total Trials
5
Recruiting
1
Active
1
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
5Total
Not Applicable (3)
P 2 (1)
P 4 (1)
Trial Status
Not Yet Recruiting2
Enrolling By Invitation1
Completed1
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT07114055Phase 2RecruitingPrimary
Effect of Ebastine in Patients With Diarrhea Predominant Irritable Bowel Syndrome
NCT07061184Phase 4Not Yet RecruitingPrimary
Fengliao Changweikang for Diarrhea-predominant Irritable Bowel Syndrome: N-of-1 Trial
NCT06837064Not ApplicableEnrolling By Invitation
Efficacy of Chatbot for Irritable Bowel Syndrome (IBS) Patients
NCT06779214Not ApplicableNot Yet RecruitingPrimary
Effect of Food-derived Active Components on Digestive Tract Health in Adults with Irritable Bowel Syndrome
NCT05157061Not ApplicableCompleted
GOS to Reduce Symptom Severity in IBS
Showing all 5 trials